Prof. Dr. MUSTAFA ERMAN

Yayın Ağı

Makaleler 97

1. The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancer

YILMAZ F., Yaşar S., Tatar O. D., Yildirim H. c., Guven D. C., TABAN H., et al.

Acta Medica , cilt.56, sa.3, ss.186-198, 2025 (TRDizin)

2. Early Changes in Volumetric Body Composition Parameters Predict Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy

AKTEPE O. H., ERDEMİR A. G., Yildirim E. C., Demirciler E., ULAŞLI T., GÜVEN D. C., et al.

JOURNAL OF CLINICAL MEDICINE , sa.9, 2025 (SCI-Expanded, Scopus)

3. The association between blood sodium levels and survival in patients treated with immune checkpoint inhibitors

ŞAHİN T. K., GÜVEN D. C., Durukan M., KAVGACI G., KAYGUSUZ Y., ARIK Z., et al.

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS , sa.4, ss.129-137, 2025 (SCI-Expanded)

4. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study

Topal A., Akdag G., Yildirim S., Kinikoglu O., Isik D., Yildirim G., et al.

MEDICINA-LITHUANIA , sa.3, 2025 (SCI-Expanded, Scopus)

5. Comparative Analysis of Prognostic Potential of Pretreatment Blood-Based Biomarkers in Metastatic Bladder Cancer: Modified Glasgow Prognostic Score

KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., Koc I., Tatar O. D., et al.

JOURNAL OF CLINICAL MEDICINE , sa.6, 2025 (SCI-Expanded, Scopus)

6. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program (EAP).

Tural D., Ozkan O., YASLIKAYA Ş., TATLI A. M., Akdag G., Demir H., et al.

JOURNAL OF CLINICAL ONCOLOGY , sa.5_SUPPL, 2025 (SCI-Expanded, Scopus)

7. The association between HALP score and survival in patients treated with immune checkpoint inhibitors

ŞAHİN T. K., GÜVEN D. C., Durukan M., BAŞ O., KAYGUSUZ Y., ARIK Z., et al.

EXPERT REVIEW OF ANTICANCER THERAPY , sa.1, ss.81-89, 2025 (SCI-Expanded)

8. Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer

YILMAZ F., YAŞAR S., Tatar O. D., Yildirim H. C., Guven D. C., AKYILDIZ A., et al.

BMC CANCER , cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)

9. Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with Immunotherapy

Degerli E., Arslan C., Selcukbiricik F., Olmez O. F., Erdem D., Hamdard J., et al.

MEDICINA-LITHUANIA , cilt.60, sa.12, 2024 (SCI-Expanded, Scopus)

10. Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder Cancer

Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Akar E., ERMAN M., et al.

CLINICAL GENITOURINARY CANCER , cilt.22, sa.6, 2024 (SCI-Expanded, Scopus)

11. Efficacy of Systemic Treatments in Patients With Metastatic Lung Invasive Mucinous Adenocarcinoma

Demir T., Araz M., Moloney C., Hendem E., Kocak M. Z., ERMAN M., et al.

CLINICAL LUNG CANCER , sa.7, 2024 (SCI-Expanded, Scopus)

12. Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors

Tural D., Arslan C., Selcukbiricik F., ÖLMEZ Ö. F., ERMAN M., ÜRÜN Y., et al.

CLINICAL GENITOURINARY CANCER , cilt.22, sa.5, 2024 (SCI-Expanded, Scopus)

13. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Guzel H. G., et al.

JOURNAL OF CHEMOTHERAPY , 2024 (SCI-Expanded, Scopus)

14. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

Lara Jr P. N., Villanueva L., Ibanez C., ERMAN M., Lee J. L., Heinrich D., et al.

BMC CANCER , cilt.23, sa.SUPPL 1, 2024 (SCI-Expanded, Scopus)

15. Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors

KAVGACI G., GÜVEN D. C., KAYGUSUZ Y., KARACA E., DİZDAR Ö., Kilickap S., et al.

SUPPORTIVE CARE IN CANCER , cilt.32, sa.7, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

16. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)

YAŞAR H. A., AKTAŞ B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., et al.

Clinical Genitourinary Cancer , cilt.22, sa.3, 2024 (SCI-Expanded, Scopus)

17. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

KILIÇKAP S., Ozturk A., Karadurmus N., KORKMAZ T., YUMUK P. F., ÇİÇİN İ., et al.

MEDICINE , cilt.103, sa.21, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

18. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study

Guven D. C., Aykan M. B., MUĞLU H., BAYRAM E., Helvaci K., DURSUN B., et al.

Cancer Medicine , cilt.13, sa.1, 2024 (SCI-Expanded, Scopus)

19. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab

YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., et al.

Journal of Immunotherapy and Precision Oncology , cilt.6, sa.4, ss.170-176, 2023 (Scopus)

20. Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

GÜNER G., AKTAŞ B. Y., Başal F. B., DEMİRKAZIK A., Gürsoy P., Demirci U., et al.

Journal of Cancer Research and Clinical Oncology , cilt.149, sa.14, ss.13271-13277, 2023 (SCI-Expanded, Scopus)

21. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study

GÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.149, sa.7, ss.3599-3606, 2023 (SCI-Expanded, Scopus)

22. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.

Anti-Cancer Drugs , cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded, Scopus)

23. Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice

Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Akar E., ERMAN M., et al.

Clinical Genitourinary Cancer , cilt.21, sa.3, ss.334-341, 2023 (SCI-Expanded, Scopus)

24. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.

INTERNATIONAL JOURNAL OF CANCER , cilt.152, ss.679-685, 2023 (SCI-Expanded, Scopus)

25. NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

de Castro G., Rizvi N. A., Schmid P., Syrigos K., Martin C., Yamamoto N., et al.

Journal of Thoracic Oncology , cilt.18, sa.1, ss.106-119, 2023 (SCI-Expanded, Scopus)

26. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.

JOURNAL OF CLINICAL MEDICINE , cilt.11, sa.17, 2022 (SCI-Expanded, Scopus)

27. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy

GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., et al.

JOURNAL OF CLINICAL MEDICINE , cilt.11, sa.15, 2022 (SCI-Expanded, Scopus)

28. The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy

GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.28, sa.4, ss.785-793, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

29. Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.

Guven D. C., Sayegh N., Tripathi N., Erman M., Agarwal N., Swami U.

JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.16, 2022 (SCI-Expanded, Scopus)

30. Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)& nbsp;

Levy B., Barlesi F., Paz-Ares L., Bennouna J., ERMAN M., Felip E., et al.

LUNG CANCER , cilt.166, ss.107-113, 2022 (SCI-Expanded, Scopus)

31. Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma

Tural D., Selcukbiricik F., Olmez O. F., Sumbul A. T., ERMAN M., COŞKUN H. Ş., et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , cilt.27, sa.3, ss.585-591, 2022 (SCI-Expanded, Scopus)

32. Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma

Ismayilov R., AKTEPE O. H., Sardarova K., LEBLEBİCİ C. B., ERMAN M.

EURASIAN JOURNAL OF MEDICINE , cilt.54, sa.1, ss.77-79, 2022 (ESCI, Scopus, TRDizin) Sürdürülebilir Kalkınma

33. Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice.

Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Erman M., Urun Y., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.6, 2022 (SCI-Expanded, Scopus)

34. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , cilt.6, sa.1, ss.59-63, 2022 (ESCI, TRDizin) Sürdürülebilir Kalkınma

35. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study

GÜVEN D. C., Acar R., Yekeduz E., Bilgetekin I., Baytemur N. K., EROL C., et al.

CURRENT PROBLEMS IN CANCER , cilt.45, sa.6, 2021 (SCI-Expanded, Scopus)

36. The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy

AKTEPE O. H., GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇELİKTEN B., Yeter H. H., et al.

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL , cilt.73, sa.10, ss.1957-1963, 2021 (SCI-Expanded, Scopus)

37. Should Protocols Specific to Histologic Subtypes Be Applied in the Follow-Up of NSCLC?

ARIK Z., ERMAN M.

JOURNAL OF THORACIC ONCOLOGY , cilt.16, sa.10, 2021 (SCI-Expanded, Scopus)

38. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.

SUPPORTIVE CARE IN CANCER , cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

39. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors

GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.

BIOMARKERS IN MEDICINE , cilt.15, sa.13, ss.1123-1130, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

40. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Blackhall F., Jao K., Greillier L., Cho B. C., Penkov K., Reguart N., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.16, sa.9, ss.1547-1558, 2021 (SCI-Expanded, Scopus)

41. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences

Tural D., Olmez O. F., Sumbul A. T., ARTAÇ M., Ozhan N., Akar E., et al.

EUROPEAN UROLOGY FOCUS , cilt.7, sa.5, ss.1061-1066, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

42. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

Tural D., Olmez O. F., Sumbul A. T., Ozhan N., ÇAKAR B., Kostek O., et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , cilt.26, ss.1506-1513, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

43. Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?

Sari S. Y., AKTAŞ B. Y., KERTMEN N., ELMALI A., Kilickap S., Oguz K. K., et al.

CUREUS , cilt.13, sa.6, 2021 (ESCI)

44. THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION , cilt.36, 2021 (SCI-Expanded, Scopus)

45. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., et al.

SUPPORTIVE CARE IN CANCER , cilt.29, sa.4, ss.2029-2035, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

46. Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma

AKTEPE O. H., GÜNER G., GÜVEN D. C., TABAN H., YILDIRIM H. Ç., ŞAHİN T. K., et al.

TURKISH JOURNAL OF UROLOGY , cilt.47, sa.2, ss.113-119, 2021 (ESCI, Scopus, TRDizin)

47. Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.

Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.6, 2021 (SCI-Expanded, Scopus)

48. Survival Outcomes of Patients in Advanced Non-Clear Renal Cell Carcinoma Treated with Pazopanib: A Retrospective Single Institution Experience

AKTEPE O. H., ERMAN M.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.31, sa.3, ss.170-177, 2021 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

49. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., et al.

LUNG CANCER , cilt.148, ss.48-54, 2020 (SCI-Expanded, Scopus)

50. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma

BAŞ O., Ozbek A., Guven D., Aktepe O., KILIÇ L., KERTMEN N., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.5, ss.1230-1233, 2020 (SCI-Expanded, Scopus)

51. Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic

Kucuk E., EKİNCİOĞLU A., ERMAN M., KILIÇKAP S.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.3, ss.595-602, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

52. Electrophysiologic evaluation of facial nerve functions after oxaliplatin treatment

Yiğit Ö., Kulak Kayıkcı M. E., Temuçin Ç. M., Sarac S., Erman M., Belgin E.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.84, sa.3, ss.513-520, 2019 (SCI-Expanded, Scopus)

53. Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability

KILIÇKAP S., Onder S., DİZDAR Ö., ERMAN M., ÜNER A.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.83, sa.6, ss.1195-1196, 2019 (SCI-Expanded, Scopus)

54. Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol

Levy B., Paz-Ares L., Bennouna J., Felip E., Rodriguez Abreu D., Isla D., et al.

CLINICAL LUNG CANCER , cilt.20, sa.3, 2019 (SCI-Expanded, Scopus)

55. Middle East observational study in metastatic soft tissue sarcoma: an epidemiological study on the treatment patterns (MOON)

Memon M. A., Karaca B., Aboelhassan R., Barsoum M., ERMAN M., Basaran M., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.144, sa.11, ss.2219-2229, 2018 (SCI-Expanded, Scopus)

56. Factors associated with quitting action following smoking cessation counseling.

Hayran K. M., Yuce D., Erman M., Dizdar O., Kilickap S., HUSEYIN B.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)

57. Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung

Levy B. P., Paz-Ares L. G., Bennouna J., Felip E., Abreu D. R., Isla D., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)

58. Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors

Tecen-Yucel K., Bayraktar-Ekincioglu A., KILIÇKAP S., ERMAN M.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.28, sa.1, ss.53-60, 2018 (SCI-Expanded, Scopus, TRDizin)

59. BİR SİGARA BIRAKMA POLİKLİNİĞİNDE UYGULANAN PSİKOEĞİTİMSEL SİGARA BIRAKMA POROGRAMININ ETKİNLİĞİ

KAMIŞLI S., YÜCE D., küçükçoban ş., HAYRAN K. M., KILIÇKAP S., ÇELİK İ., et al.

Anadolu Hemşirelik ve Sağlık Bilimleri Dergisi , cilt.20, sa.4, ss.234-242, 2017 (TRDizin)

60. Survival following laparoscopic adrenalectomy for solitary metastasis of lung cancer

Tonyali S., HABERAL H. B., Yazici S., ERMAN M., KAYNAROĞLU Z. V., BİLEN C. Y.

INTERNATIONAL UROLOGY AND NEPHROLOGY , cilt.48, sa.11, ss.1803-1809, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

61. Vaccination perception and attitudes among patients with cancer receiving chemotherapy

AKIN Ş., DİZDAR Ö., Karakas Y., ÖZIŞIK L., Tanriover M. D., Kamisli S., et al.

ANNALS OF ONCOLOGY , cilt.27, 2016 (SCI-Expanded, Scopus)

62. Renal cell cancer: overview of the current therapeutic landscape

ERMAN M., Benekli M., Basaran M., BAVBEK S., Buyukberber S., Coskun U., et al.

EXPERT REVIEW OF ANTICANCER THERAPY , cilt.16, sa.9, ss.955-968, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

63. Effect of Zoledronic Acid on Rats' Tissue SDF-1 Expression

Arik Z., KILIÇKAP S., AKPULAT U., Nahit Sendur M. A., KOCAEFE Y. Ç., ERMAN M.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.4, ss.215-219, 2016 (SCI-Expanded, Scopus, TRDizin)

64. Vaccination Attitudes Among Patients with Cancer Receiving Chemotherapy

AKIN S., DİZDAR Ö., ÖZIŞIK L., TANRIOVER M., KAMISLI S., ERMAN M., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.3, ss.167-172, 2016 (SCI-Expanded, Scopus, TRDizin)

65. QUALITY OF LIFE DOMAINS ASSOCIATED WITH READMISSION

HAYRAN K. M., YÜCE D., Huseyin B., Esin E., KILIÇKAP S., ERMAN M., et al.

VALUE IN HEALTH , cilt.18, sa.3, 2015 (SCI-Expanded, SSCI, Scopus)

66. Nationwide Smoking Cessation Treatment Support Program - Turkey project

ÇELİK İ., YÜCE D., Hayran M., ERMAN M., KILIÇKAP S., BUZĞAN T., et al.

HEALTH POLICY , cilt.119, sa.1, ss.50-56, 2015 (SCI-Expanded, SSCI, Scopus) Sürdürülebilir Kalkınma

67. ASSOCIATION OF HEALTH CARE COST WITH QUALITY OF LIFE FOR VARIOUS TYPES OF CANCERS

HAYRAN K. M., YÜCE D., Huseyin B., Esin E., KILIÇKAP S., ERMAN M., et al.

VALUE IN HEALTH , cilt.17, sa.7, 2014 (SCI-Expanded, SSCI, Scopus)

68. HEALTH RELATED QUALITY OF LIFE IN CANCER PATIENTS: EVALUATION WITH A SELF-ADMINISTERED IPAD APPLICATION

YÜCE D., HAYRAN K. M., KILIÇKAP S., ERMAN M., ÇELİK İ.

VALUE IN HEALTH , cilt.17, sa.7, 2014 (SCI-Expanded, SSCI, Scopus)

69. Aromatase Inhibitors and Safety: Clinical or Statistical Significance?

Esin E., YÜCE D., KILIÇKAP S., ERMAN M.

JOURNAL OF CLINICAL ONCOLOGY , cilt.31, sa.27, ss.3439, 2013 (SCI-Expanded, Scopus)

70. Effect of Endocrine Therapy on Quality of Life and Cognitive Functions in Patients with Breast Cancer

KILIÇKAP S., HAYRAN M., ÇAKIR B., ÇİLİNGİROĞLU N., ERMAN M., Buyukdamgaci G., et al.

BREAST CARE , cilt.8, sa.2, ss.128-132, 2013 (SCI-Expanded, Scopus)

71. Pituitary Gland Metastasis of Breast Cancer: A Case Report

Ozkan C., ARSLAN Ç., KILIÇ M., ERMAN M., Altundag K.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.22, sa.1, ss.42-45, 2012 (SCI-Expanded, Scopus, TRDizin)

72. Isolated Bone Metastases in Early Stage Endometrial Adenocarcinoma: A Case Report and Review of the Literature

Kurt M., KILIÇKAP S., AKSOY S., ERMAN M., Gedikoglu G., Turker A.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.21, sa.1, ss.52-56, 2011 (SCI-Expanded, Scopus, TRDizin)

73. FREQUENCY OF CANCER TYPES IN PATIENTS AGED 65 AND OLDER: RESULTS FROM CANCER REGISTRY DATABASE OF HACETTEPE UNIVERSITY HOSPITALS

Arslan C., KILIÇKAP S., Dede D. S., HAYRAN K. M., ERMAN M., ÇELİK İ., et al.

TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI , cilt.14, sa.3, ss.187-192, 2011 (SCI-Expanded, SSCI, Scopus, TRDizin) Sürdürülebilir Kalkınma

74. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma

KILIÇKAP S., Yavuz B., AKSOY S., Sahiner L., DİNÇER M., HARPUTLUOĞLU H., et al.

MEDICAL ONCOLOGY , cilt.25, sa.4, ss.437-442, 2008 (SCI-Expanded, Scopus)

75. Platelet size has diagnostic predictive value for bone marrow metastasis in patients with solid tumors

AKSOY S., KILIÇKAP S., Hayran M., HARPUTLUOĞLU H., KOCA E., Dede D. S., et al.

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY , cilt.30, sa.3, ss.214-219, 2008 (SCI-Expanded, Scopus)

76. Erectile dysfunction in successfully treated lymphoma patients

AKSOY S., HARPUTLUOĞLU H., KILIÇKAP S., DİNÇER M., DİZDAR Ö., AKDOĞAN B., et al.

SUPPORTIVE CARE IN CANCER , cilt.16, sa.3, ss.291-297, 2008 (SCI-Expanded, Scopus)

77. A decision-analytic model for early stage breast cancer: Lumpectomy vs mastectomy

Alogan G. B., Elele T., Hayran M., ERMAN M., KILIÇKAP S.

NEOPLASMA , cilt.55, sa.3, ss.222-228, 2008 (SCI-Expanded, Scopus)

78. Vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and cyclooxygenase-2 expression in psoriasis

YALÇIN B., Tezel G. G., ARDA N., ERMAN M., ALLI N.

ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY , cilt.29, sa.6, ss.358-364, 2007 (SCI-Expanded, Scopus)

79. Molecular mechanisms of signal transduction: Epidermal growth factor receptor family, Vascular endothelial growth factor family, Kit, Platelet-derived growth factor receptor, Ras

Erman M.

JOURNAL OF BUON , cilt.12, 2007 (SCI-Expanded, Scopus)

80. Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab

Kalyoncu U., Karadag O., Akdogan A., KISACIK B., Erman M., Erguven S., et al.

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES , cilt.39, sa.5, ss.475-478, 2007 (SCI-Expanded, Scopus)

81. Thymic epithelial neoplasia - A study of 58 cases

ELKIRAN E. T., Abali H., Aksoy S., Altundag K., Erman M., Kars A., et al.

MEDICAL ONCOLOGY , cilt.24, sa.2, ss.197-201, 2007 (SCI-Expanded, Scopus)

82. Expressions of vascular endothelial growth factor and CD34 in oral aphthous lesions of Behcet's disease

YALÇIN B., ARDA N., Tezel G. G., ERMAN M., ALLI N.

ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY , cilt.28, sa.6, ss.303-306, 2006 (SCI-Expanded, Scopus)

83. Extensive exfoliative dermatitis induced by chlorambucil

Kilickap S., Kurt M., Aksoy S., Erman M., Turker A.

AMERICAN JOURNAL OF HEMATOLOGY , cilt.81, sa.11, ss.891-892, 2006 (SCI-Expanded, Scopus)

84. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient

Aksoy S., Abali H., Kilickap S., Erman M., Kars A.

CLINICAL AND LABORATORY HAEMATOLOGY , cilt.28, sa.3, ss.211-214, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

85. Nasopharynx carcinoma complicated with pneumocephalus

Dizdar O., Kilickap S., Aksoy S., Cizginer S., Erman M.

JOURNAL OF NEURO-ONCOLOGY , cilt.77, sa.1, ss.107-108, 2006 (SCI-Expanded, Scopus)

86. Lithium-associated hypothyroidism and thyroid papillary carcinoma: A case report

Aksoy S., Kilickap S., Erman M.

SOUTHERN MEDICAL JOURNAL , cilt.99, sa.3, ss.279-281, 2006 (SCI-Expanded, Scopus)

87. Metastatic granular cell tumor: A case report and review of the literature

Aksoy S., Abali H., Kilickap S., HARPUTLUOĞLU H., Erman M.

ACTA ONCOLOGICA , cilt.45, sa.1, ss.91-94, 2006 (SCI-Expanded, Scopus)

88. Nonconvulsive status epilepticus due to ifosfamide

Kilickap S., ÇAKAR M., Onal I., Tufan A., Akoglu H., Aksoy S., et al.

ANNALS OF PHARMACOTHERAPY , cilt.40, sa.2, ss.332-335, 2006 (SCI-Expanded, Scopus)

89. Ovarian carcinoma in two patients with chronic liver disease

Isildak M., SAİN GÜVEN G., Kekilli M., Beyazit Y., ERMAN M.

WORLD JOURNAL OF GASTROENTEROLOGY , cilt.11, sa.28, ss.4445-4446, 2005 (SCI-Expanded, Scopus)

90. Multivariate analysis of factors predictive of brain metastases in localised non-small call lung carcinoma

Kilickap S., Aksoy S., Erman M.

LUNG CANCER , cilt.49, sa.1, ss.129, 2005 (SCI-Expanded, Scopus)

91. Fludarabine phosphate may be useful in the treatment of graft-versus-host disease

Aksoy S., Abali H., Kilickap S., DİNÇER M., Erman M.

MEDICAL HYPOTHESES , cilt.64, sa.6, ss.1150-1152, 2005 (SCI-Expanded, Scopus)

92. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?

Erman M., Abali H., ORAN B., Haznedaroglu I., Canpinar H., KİRAZLI Ş., et al.

ANNALS OF ONCOLOGY , cilt.15, sa.11, ss.1622-1626, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

93. Analysis of menstrual, reproductive, and life-style factors for breast cancer risk in Turkish women - A case-control study

ORAN B., Celik I., Erman M., BALTALI E., ZENGİN N., Demirkazik F., et al.

MEDICAL ONCOLOGY , cilt.21, sa.1, ss.31-39, 2004 (SCI-Expanded, Scopus)

94. Coincidental detection of T-cell rich B cell lymphoma in the para-aortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer: A case report

Abali H., Eren O. Ö., Erman M., Uner A., Kose F., GÜLER N.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , cilt.13, sa.5, ss.687-689, 2003 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

95. Concomitant Mycobacterium tuberculosis and Aspergillus niger infection in a patient with acute myeloid leukemia

AKSOY D., TURKER A., ALTUNDAG M. K., ABALI H., DURUSU M., ERMAN M., et al.

CHEMOTHERAPY , cilt.49, sa.5, ss.264-266, 2003 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

96. Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis

ARIKAN S., AKOVA M., HAYRAN M., OZDEMIR O., ERMAN M., GUR D., et al.

CLINICAL INFECTIOUS DISEASES , cilt.26, sa.4, ss.903-908, 1998 (SCI-Expanded, Scopus)

97. A randomized multicenter comparative study of cefepime and ceftazidime in combination with amikacin in the treatment of patients with fever and neutropenia

ERMAN M., Akan H., KORTEN V., Ferhanoǧlu B., UZUN Ö., ÜNAL S., et al.

Clinical Infectious Diseases , cilt.25, sa.2, ss.463, 1997 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 17

1. Efficacy of systemic treatments in patients with metastatic lung invasive mucinous adenocarcinoma

Demir T., Araz M., Hendem E., Kocak M. Z., Erman M., Bas O., et al.

Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)

2. Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience

Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., et al.

Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38, (Özet Bildiri)

3. BİR ÜNİVERSİTENİN SİGARA BIRAKMA ÜNİTESİNE BAŞVURANLARIN ÖZELLİKLERİ VE SİGARA BIRAKMA OLASILIKLARI

ŞENGELEN M., ÇELİK İ., ERMAN M., Tezcan S., YÜCE D., Kamışlı S., et al.

2. ULUSLARARASI 20. ULUSAL HALK SAĞLIĞI KONGRESİ, Antalya, Türkiye, 13 - 17 Kasım 2018, (Özet Bildiri)

4. TRANSCULTURAL ADAPTATION OF EORTC-QLQ-CR29 SCALE INTO TURKISH, AND ASSESSMENT OF VALIDITY ANDRELIABILITY IN TURKISH PATIENTS WITH COLORECTAL CANCER

HAYRAN K. M., YÜCE D., KILIÇKAP S., houssein b., ERMAN M., DİZDAR Ö., et al.

ISPOR Asia Pacific 2018, Tokyo, Japonya, 8 - 11 Kasım 2018, cilt.1, ss.11, (Tam Metin Bildiri)

5. EFFECTS OF CANCER TYPES ON LOCAL AND OUT-OF-CITY ADMISSIONS FOR MEDICAL CARE

HAYRAN K. M., YÜCE D., KILIÇKAP S., DİZDAR Ö., houssein b., ERMAN M., et al.

ISPOR Asia Pacific 2018, Tokyo, Japonya, 8 - 11 Kasım 2018, (Özet Bildiri) Sürdürülebilir Kalkınma

6. İki olgu nedeniyle Nivolimumaba bağlı akciğer toksisitesi

BABAOĞLU E., SARINÇ ULAŞLI S., KÖKSAL D., ERMAN M., BARIŞTA İ.

Ulusal Akciğer Sağlığı Kongresi, Türkiye, 14 - 18 Mart 2018, (Özet Bildiri)

7. Brain Tissue Follow-up Using Dynamic Susceptibility Contrast-Enhanced and Dynamic Contrast-Enhanced Perfusion Magnetic Resonance Imaging on Lesions Categorized by Apparent Diffusion Coefficient Values in Glioblastoma

OMAY B., ARDALI S., MUT AŞKUN M., KILIÇKAP S., ERMAN M., KARLI OĞUZ H. K.

Radiology Society of North America, 26 Kasım - 01 Aralık 2017, (Özet Bildiri)

8. Efficiency of a psychoeducational Intervention for smoking cessation in a specialized cessation clinic

YÜCE D., KAMIŞLI S., KÜÇÜKÇOBAN ş., HAYRAN K. M., KILIÇKAP S., ÇELİK İ., et al.

2017 World Congress of Psycho-Oncology, 14 - 18 Ağustos 2017, (Özet Bildiri)

9. Metastatik kastrasyona dirençli prostat kanser hastalarında kabazitakselin güvenlik verileri: Kabazitaksel Türkiye insani amaçlı ilaca erişim programı sonuçları

BAVBEK S., BAŞARAN M., ÖZEN A. H., ERMAN M., ÖZDOĞAN M., ÖZGÜROĞLU M., et al.

22. ULUSAL KANSER KONGRESİ, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

10. Smoker relatives of inpatients: A reasonable but heterogeneous target population for smoking cessation program

AKTAŞ B. Y., HOUSSEİN b., YÜCE D., DİZDAR Ö., KILIÇKAP S., ERMAN M., et al.

7th ECTOH Conference on Tobacco or Health, Porto, Portekiz, 22 - 25 Mart 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

11. Tirozin Kinaz İnhibitörü Kaynaklı Tiroid Fonksiyon Bozukluğu

TECEN K., ÖZDEMİR N., KARA E., EKİNCİOĞLU A., DEMİRKAN S. K., ERMAN M., et al.

18. ULUSAL İÇ HASTALIKLARI KONGRESİ, Türkiye, 12 - 16 Ekim 2016, (Özet Bildiri)

12. Using geographical information systems to describe quality of life as a function of distance in cancer patients

HAYRAN K. M., ERMAN M., KILIÇKAP S., DİZDAR Ö., YÜCE D., HÜSEYİN B., et al.

ISPOR Asia Pacific Meeting 2016, 3 - 06 Eylül 2016, cilt.19, ss.892, (Özet Bildiri)

13. Factors that affect the suitability of cancer patients for clinical drug trials in Turkey: Final analysis of a multicenter study.

Erman M., Kilickap S., Ekinci A. S., Koca S., Ata A., Besen A., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) Sürdürülebilir Kalkınma

14. Temporal changes in the survival of metastatic renal cell cancer patients and the impact of targeted agents: Single center experience

Erman M., Arik Z., Kilickap S., Bilen C. Y., Yazici S., Akdogan B., et al.

Genitourinary Cancers Symposium, San-Francisco, Kostarika, 30 Ocak - 01 Şubat 2014, cilt.32, (Özet Bildiri) Sürdürülebilir Kalkınma

Kitaplar 1

1. Kastrasyona dirençli prostat kanseri tedavisi

ERMAN M., ARIK Z.

Üroonkoloji Kitabı, , Editör, Nobel, 2018

Metrikler

Yayın

115

Yayın (WoS)

103

Yayın (Scopus)

Atıf (WoS)

429

H-İndeks (WoS)

Atıf (Scopus)

453

H-İndeks (Scopus)

Proje

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler